Skip to main content
The Compelling Case for Therapeutic Drug Monitoring of Mycophenolate Mofetil Therapy
Pediatric Mephrology
  • Guido Filler, Western University
  • Ana Catalina Alvarez-Elías, Western University
  • Christopher McIntyre, Western University
  • Mara Medeiros, Universidad Nacional Autónoma de México
Document Type
Publication Date
URL with Digital Object Identifier

We have reviewed current evidence on the therapeutic drug monitoring (TDM) of mycophenolic acid (MPA) in relationship to drug efficacy and safety. The relationship between actual MPA exposure and mycophenolate mofetil (MMF) dose has been shown to be weak in children and adolescents. The TDM of MPA exposure should ideally be performed using full pharmacokinetic profiles or limited sampling strategies. Recent evidence has provided some rationale for using the post-dose trough level as a single measure. In terms of short-term efficacy, there is strong evidence that a MPA area under the time-concentration curve of >30 mg × h/L reduces acute rejection episodes early after renal transplantation, and there is evolving evidence that aiming for the same exposure over the long term may be a viable strategy to reduce the formation of donor-specific antibodies. Strong evidence also supports the existence of important drug interactions and age/developmental dependent differences in drug metabolism that may necessitate the need for TDM of MMF therapy. Based on these findings and given the substantial inter- and intra-patient variability of MPA exposure, it would appear that MMF therapy should be subject to TDM to avoid over- and under-dosing. This may be a viable strategy to reduce treatment-emergent adverse events and to increase the effective pediatric transplant survival rates.

Citation Information
Guido Filler, Ana Catalina Alvarez-Elías, Christopher McIntyre and Mara Medeiros. "The Compelling Case for Therapeutic Drug Monitoring of Mycophenolate Mofetil Therapy" Pediatric Mephrology Vol. 32 Iss. 1 (2017) p. 21 - 29
Available at: